{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.08","upperLimit":"1.74","value":"1.41"},{"groupId":"OG001","lowerLimit":"1.15","upperLimit":"6.28","value":"1.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the time from first dosing date to the date of the first documented progression using the IPCG Criteria for PCNSL and Lugano 2014 response evaluation for PTL, as determined by BICR, or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG000","title":"PCNSL Cohort"},{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Testicular Lymphoma (PTL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG001","title":"PTL Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated PCNSL and PTL participants","reportingStatus":"POSTED","timeFrame":"Up to approximately 51 months","title":"BICR-Assessed Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}